Immutep (ASX:IMM) said its phase 2b trial evaluating eftilagimod alpha in combination with Keytruda for patients with head and neck squamous cell cancer showed "strong" overall survival, progression-free survival, and durability, according to a Thursday filing with the Australian bourse.
The 12-month overall survival rate was 67%, well above historical controls, while the interim median duration of response was 9.3 months, the filing said. The median overall survival has not yet been reached.
The Tacti-003 study also found the combination therapy continues to be well-tolerated, with no new safety concerns identified, the filing said.
The biotechnology company's shares rose nearly 3% in afternoon trade Thursday.
Price (AUD): $0.37, Change: $+0.01, Percent Change: +2.82%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。